CSChristoph Sotriffer

Christoph Sotriffer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Christoph Sotriffer has a total of 229 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Human-targeted drugs impact antibiotic sensitivity and growth of Campylobacter jejuni

    by Annamaria Zannoni, Roberto Olayo-Alarcon, Martin K. Amstalden, Medina Feldl, Rebecca Würz, Thea Bruchhardt, Johannes Kullmann, Sarah L. Svensson, Christoph Sotriffer, Mona Alzheimer, et al.

    Antibiotic resistance is increasingly recognized as a major threat to global health, yet the contribution of non-antibiotics to this problem remains poorly defined. Here, we established a transcriptional chemical genomics approach to map how 2,415 host-relevant small molecules influence stress-responsive promoters and fitness of the foodborne pathogen Campylobacter jejuni. This screen uncovered widespread activation of the CmeABC efflux pump by diverse compounds, including several human-targeted drugs. Notably, ibuprofen, one of the most widely used non-steroidal anti-inflammatory drugs worldwide, induced efflux pump expression and thereby enhanced bacterial tolerance to ciprofloxacin. We also identified multiple commensal-sparing human-targeted drugs with growth-inhibitory activity against C. jejuni , highlighting opportunities for pathogen-targeted drug repurposing. Together, our findings reveal that non-antibiotic drugs can both promote resistance-associated phenotypes and selectively suppress pathogen growth. This underscores the need to consider collateral drug effects on bacterial physiology when designing strategies to curb the burden of antimicrobial resistance.

  • Structural Optimization of Covalent Inhibitors for Deubiquitinase ChlaDUB1 of Chlamydia trachomatis as Antibiotic Agents

    by Thomas Zimmermann, Jiachen Feng, Simon Fischer, Luana Janaína de Campos, Felipe Ramos Pinheiro, Christoph Sotriffer, Martin Conda-Sheridan, Michael Decker

    The cysteine protease ChlaDUB1 has proven to be a promising new target for antichlamydial therapy. This deubiquitinase manipulates protein homeostasis of the infected human host cell, concealing the chlamydial infection. In this study, we optimized a previously identified scaffold of covalently acting ChlaDUB1 inhibitors using a combination of docking, synthesis and in vitro enzymatic screening. This led to a reduction of the inhibitor size while simultaneously improving activity at ChlaDUB1 to 1 μM and enhancing the rate of target inhibition. We identified a hitherto unobserved inhibition mechanism at ChlaDUB1 and narrowed it down to a particular substitution pattern by chemical derivatization. Finally, both antichlamydial activity and cytotoxicity of the lead compounds were determined. Hereby, we present comprehensive structure-activity relationships and detailed kinetic studies that identified a small molecule lead compound for specific antichlamydial therapy, which showed drastically lowered cytotoxicity compared to previously described compounds.


  • Correlating Predicted Reactivities with Experimental Inhibition Data of Covalent ChlaDUB1 Inhibitors

    by Thomas Zimmermann, Erik Endres, Christoph Sotriffer, Michael Decker

    Covalent inhibition with electrophiles of suitable reactivity allows for prolonged inactivation of a targeted enzyme, in comparison to noncovalent inhibitors. To fine-tune covalently reacting groups, various computational workflows have been developed for reactivity prediction. Their results are typically evaluated based on in vitro assays that use cysteine, glutathione, or other model nucleophiles, but the relevance of the predictions for the situation in a particular enzyme environment remains under-investigated. Herein, we utilized a DFT-based computational method to assess the transferability of predicted reactivities to enzyme inhibition. For this, we designed and synthesized a set of covalent inhibitors of ChlaDUB1, a potential target to fight the pathogen Chlamydia trachomatis. We show that in the context of enzyme inhibition, geometrical congruence between ligands has to be taken into account when evaluating the reactivity of covalently reacting groups in respective drug discovery projects.


  • Open Access

    Structural basis for the bi-specificity of USP25 and USP28 inhibitors

    by Jonathan Vincent Patzke, Florian Sauer, Radhika Karal Nair, Erik Endres, Ewgenij Proschak, Victor Hernandez-Olmos, Christoph Sotriffer, Caroline Kisker

    The development of cancer therapeutics is often hindered by the fact that specific oncogenes cannot be directly pharmaceutically addressed. Targeting deubiquitylases that stabilize these oncogenes provides a promising alternative. USP28 and USP25 have been identified as such target deubiquitylases, and several small-molecule inhibitors indiscriminately inhibiting both enzymes have been developed. To obtain insights into their mode of inhibition, we structurally and functionally characterized USP28 in the presence of the three different inhibitors AZ1, Vismodegib and FT206. The compounds bind into a common pocket acting as a molecular sink. Our analysis provides an explanation why the two enzymes are inhibited with similar potency while other deubiquitylases are not affected. Furthermore, a key glutamate residue at position 366/373 in USP28/USP25 plays a central structural role for pocket stability and thereby for inhibition and activity. Obstructing the inhibitor-binding pocket by mutation of this glutamate may provide a tool to accelerate future drug development efforts for selective inhibitors of either USP28 or USP25 targeting distinct binding pockets.


  • Open Access

    Improvement of Inhibitors of the Macrophage Infectivity Potentiator Protein from Trypanosoma cruzi, Burkholderia pseudomallei, and Legionella pneumophila – a Comparison

    by Theresa Lohr, Carina Herbst, Nicole Bzdyl, Christopher Jenkins, Nicolas Scheuplein, Wisely Oki Sugiarto, Jacob Whittaker, Albert Guskov, Isobel Norville, Ute Hellmich, et al.

    The treatment of Chagas disease and infections with Gram-negative bacteria is limited to a low number of antibiotics. Due to the development of resistance and partially severe side effects, there is an urgent need for new treatment strategies and virulence factors such as the macrophage infectivity potentiator (MIP) protein have emerged as a promising new therapeutic target. Inhibition of microbial MIP proteins leads to reduced viability and proliferation in pathogens such as Legionella pneumophila and Burkholderia pseudomallei. The parasitic pathogen of Chagas disease, Trypanosoma cruzi, also expresses a MIP protein, presumably involved in host cell invasion. Here, we took advantage of a compound library initially designed to inhibit MIPs of Burkholderia (BpMIP) and Legionella (LpMIP), to screen compounds against the Trypanosoma-MIP (TcMIP). Using a fluorescence polarization assay (FPA), the first qualitative structure-activity relationships could be derived. Further compound development led to highly active inhibitors of all tested MIPs from pathogenic microorganisms. Docking studies, molecular dynamics simulations and quantum mechanical calculations suggest an extended σ-hole of the meta-halogenated phenyl sulfonamide to be responsible for the high affinity.

  • Open Access

    Assessment of fragment docking and scoring with the endothiapepsin model system

    by Carina Herbst, Sara Endres, Rebecca Würz, Christoph Sotriffer

    Fragment‐based screening has become indispensable in drug discovery. Yet, the weak binding affinities of these small molecules still represent a challenge for the reliable detection of fragment hits. The extent of this issue was illustrated in the literature for the aspartic protease endothiapepsin: When seven biochemical and biophysical in vitro screening methods were applied to screen a library of 361 fragments, very poor overlap was observed between the hit fragments identified by the individual approaches, resulting in high levels of false positive and/or false negative results depending on the mutually compared methods. Here, the reported in vitro findings are juxtaposed with the results from in silico docking and scoring approaches. The docking programs GOLD and Glide were considered with the scoring functions ASP, ChemScore, ChemPLP, GoldScore, DSXCSD, and GlideScore. First, the ranking power and scoring power were assessed for the named scoring functions. Second, the capability of reproducing the crystallized fragment binding modes was tested in a structure‐based redocking approach. The redocking success notably depended on the ligand efficiency of the considered fragments. Third, a blinded virtual screening approach was employed to evaluate whether in silico screening can compete with in vitro methods in the enrichment of fragment databases.


  • Combined In-Solution Fragment Screening and Crystallographic Binding-Mode Analysis with a Two-Domain Hsp70 Construct

    by Markus Zehe, Josef Kehrein, Curd Schollmayer, Christina Plank, Helena Kovacs, Eduardo Merino Asumendi, Ulrike Holzgrabe, Clemens Grimm, Christoph Sotriffer

    Heat shock protein 70 (Hsp70) isoforms are key players in the regulation of protein homeostasis and cell death pathways and are therefore attractive targets in cancer research. Developing nucleotide-competitive inhibitors or allosteric modulators, however, has turned out to be very challenging for this protein family, and no Hsp70-directed therapeutics have so far become available. As the field could profit from alternative starting points for inhibitor development, we present the results of a fragment-based screening approach on a two-domain Hsp70 construct using in-solution NMR methods, together with X-ray-crystallographic investigations and mixed-solvent molecular dynamics simulations. The screening protocol resulted in hits on both domains. In particular, fragment binding in a deeply buried pocket at the substrate-binding domain could be detected. The corresponding site is known to be important for communication between the nucleotide-binding and substrate-binding domains of Hsp70 proteins. The main fragment identified at this position also offers an interesting starting point for the development of a dual Hsp70/Hsp90 inhibitor.


  • Molecular Dynamics Simulations for Rationalizing Polymer Bioconjugation Strategies: Challenges, Recent Developments, and Future Opportunities

    by Josef Kehrein, Christoph Sotriffer

    The covalent modification of proteins with polymers is a well-established method for improving the pharmacokinetic properties of therapeutically valuable biologics. The conjugated polymer chains of the resulting hybrid represent highly flexible macromolecular structures. As the dynamics of such systems remain rather elusive for established experimental techniques from the field of protein structure elucidation, molecular dynamics simulations have proven as a valuable tool for studying such conjugates at an atomistic level, thereby complementing experimental studies. With a focus on new developments, this review aims to provide researchers from the polymer bioconjugation field with a concise and up to date overview of such approaches. After introducing basic principles of molecular dynamics simulations, as well as methods for and potential pitfalls in modeling bioconjugates, the review illustrates how these computational techniques have contributed to the understanding of bioconjugates and bioconjugation strategies in the recent past and how they may lead to a more rational design of novel bioconjugates in the future.


  • MD-Based Assessment of Covalent Inhibitors in Noncovalent Association Complexes: Learning from Cathepsin K as a Test Case

    by Erik Endres, Natalia Yuan Chen, Christoph Sotriffer

    A sufficiently stable noncovalent association complex between a covalent inhibitor and its protein target is regarded as a prerequisite for the formation of a covalent complex. As this transient form can hardly be assessed experimentally, computational modeling is required to probe the suitability of a given ligand at this particular stage. To investigate which criteria should be fulfilled by suitable candidates in a molecular dynamics (MD) assessment, a systematic study was conducted with 20 complexes of cathepsin K, a papain-like cysteine protease of pharmaceutical relevance. The covalent inhibitors in these complexes were converted to their pre-reaction states, and the resulting noncovalent complexes were subjected to MD simulations. The critical distance between the electrophilic and nucleophilic reaction partners was monitored as a potential parameter to assess the suitability for covalent bond formation. Across various warhead types, a distance between 3.6 and 4.0 Å, comparable to the sum of the generalized Born radii of carbon and sulfur, was found to be stably maintained under appropriate conditions. The protonation state of the catalytic dyad and the resulting solvation pattern dramatically affected the noncovalent binding mode and the distance of the warhead to the active site. For several complexes, fluctuations in the orientation of the warhead were observed due to torsional rotations in adjacent bonds. This observation helped to explain the gradual transitions from noncovalent to covalent complexes observed in the crystal structures of three closely related nitrile-based inhibitors. According to comparative simulations conducted for a set of 13 cathepsin S complexes, the overall findings of the study appear to be transferable to related cysteine proteases as targets of covalent inhibitors.


  • Open Access

    Unraveling an Alternative Mechanism in Polymer Self-Assemblies: An Order–Order Transition with Unusual Molecular Interactions between Hydrophilic and Hydrophobic Polymer Blocks

    by Lukas Hahn, Theresa Zorn, Josef Kehrein, Tobias Kielholz, Anna-Lena Ziegler, Stefan Forster, Benedikt Sochor, Ekaterina S. Lisitsyna, Nikita A. Durandin, Timo Laaksonen, et al.